Emmanuel Katsaros is a Rheumatology/Immunology physician affiliated with Western University of Health Sciences. OpenAlex indexes 17 publications with 352 citations (h-index 8); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
795 E 2nd St Ste 7
Pomona, CA 917662007
Telephone
909-865-2565Provider last certified this registry record 22 Jun 2021.
Clinical trials
- The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
Sponsor: Loma Linda University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year20251 payment
- Janssen Biotech, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.3%Folate Analog Metabolic Inhibitor23.8%Methotrexate100%Part D≥20 patientsTNF inhibitor14.3%Enbrel Sureclick41%Humira(Cf) Pen32%Humira27%Part D<11 patients+ 2 more classes in this area
Antiparasitic
11.7%Antimalarial11.7%Hydroxychloroquine Sulfate100%Part D≥18 patientsMetabolism & gastrointestinal
11.7%Corticosteroid11.7%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Factors Underlying Failure of Methotrexate Treatment in Rheumatoid Arthritis: Implications in Personalized Care
Archives of Internal Medicine Research
2025 - Differential Gene Expression in Rheumatoid Arthritis: Implication in the Diagnosis and Individualized Treatment Plan
Journal of Biotechnology and Biomedicine
2025 - ABS0806 MRI FINDINGS IN SUBJECTS WITH INFLAMMATORY BACK PAIN SEEKING CARE IN A COMMUNITY-BASED PRIMARY CARE CENTER
Annals of the Rheumatic Diseases
2025 - Investigating the Use of Denosumab in the Treatment of Acute Charcot Neuroarthropathy
The Journal of Foot & Ankle Surgery
2020 - Building Interprofessional Competencies Into Medical Education and Assessment
Advances in medical education, research, and ethics (AMERE) book series
2020
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”